Fujitsu has entered a partnership agreement with the Hungarian biometrics company, BioSec Group Ltd, aiming to cover the EMEIA region. The partnership focuses on BioSec’s palm vein recognition-based products, which will be available in the Fujitsu product range, including BioSec’s physical access control-, IT security- and stadium security products.
Fujitsu will sell Budapest-based BioSec solutions in the EMEIA region, including the StadiumGuard for stadia. The firms describe the products as an alternative for passwords, PIN codes, keys, cards and tokens; as biometrics are something the user is, people do not have to remember passwords or search for keys and access cards.
According to BioSec, the future’s security is in our hands, more precisely in our veins, as our vein pattern is an absolutely unique physical characteristic, which provides “material” for secure authentication.
BioSec reports that it has been developing biometrics based on Fujitsu’s PalmSecure technology for almost a decade. Despite large numbers of people of different ages and abilities, BioSec says that its product has shown that high security should not compromise user experience. The product for example is in use at the Budapest University of Technology and Economics’s building Z.
Visit www.biosecgroup.com.
